Tadalafil Tablet, Film Coated
Product Images NDC 71335-1255

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 71335-1255). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl713351255)

This is a medication package containing Tadalafil 20mg tablets with the NDC number 7133512551. The tablets are yellow, oval, and marked with "20;S". The instructions mention storing the medication at room temperature between 20-25°C (68°-77°F) and keeping it out of reach of children. The package contains 30 tablets and has an expiration date listed as MM/YY, which is not visible in the text.*

FDA Label Image

Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)

This appears to be a table or chart showing measurements of blood pressure (systolic and diastolic) in different positions (standing and supine) before and after taking a medication (Tadalafil compared to a placebo). It also includes a time scale in hours. However, the formatting and readability are poor due to errors, so the information may not be entirely accurate.*

FDA Label Image

Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)

This is a chart displaying the standing and supine systolic blood pressure in mmHg at various times post-dose for individuals taking either tadalafil 20 mg and doxazosin 8 mg or placebo and doxazosin 8 mg.*

FDA Label Image

Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)

FDA Label Image

Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)

This is a graph showing plasma concentration of tadalafil at different doses and administration frequencies over time. The graph shows that a single 20mg dose produces a higher peak concentration compared to a single 5mg dose or daily 5mg dose given for 5 days. Tadalafil concentration decreases over time for all doses and administration frequencies.*

FDA Label Image

Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)

The text describes the change from baseline in IPSS total score and a comparison between Tadalafil 5mg and Placebo, with statistical significance marked by p<0.01. The duration of treatment in weeks is also mentioned.*

FDA Label Image

Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)

This data represents the change in IPSS total score between Tadalafil 5mg and a placebo over a treatment duration of 12 weeks. The graph shows a statistical significance (p<0.01) between the groups.*

FDA Label Image

Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)

This text presents the change from baseline in IPSS total score in a clinical trial. The information is compared between Tadalafil 5 mg and Placebo, showing a statistically significant difference with p<0.01. The duration of treatment in weeks is not specified.*

FDA Label Image

Spl-tadalafil-structure (Spl Tadalafil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.